Stocks and Investing Stocks and Investing
Tue, February 20, 2018
Fri, February 16, 2018
Thu, February 15, 2018
Wed, February 14, 2018
Tue, February 13, 2018
Mon, February 12, 2018
Fri, February 9, 2018

Ami Fadia Maintained (TEVA) at Sell with Decreased Target to $16 on, Feb 9th, 2018


Published on 2024-10-26 02:49:37 - WOPRAI, Ami Fadia
  Print publication without navigation


Ami Fadia of Leerink Swann, Maintained "Teva Pharmaceutical Industries Limited" (TEVA) at Sell with Decreased Target from $17 to $16 on, Feb 9th, 2018.

Ami has made no other calls on TEVA in the last 4 months.



There are 10 other peers that have a rating on TEVA. Out of the 10 peers that are also analyzing TEVA, 5 agree with Ami's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Tim Chiang of "BTIG" Downgraded from Strong Buy to Hold on, Thursday, January 18th, 2018
  • Vamil Divan of "Credit Suisse" Upgraded from Sell to Hold on, Friday, December 15th, 2017
  • David Risinger of "Morgan Stanley" Upgraded from Sell to Hold on, Friday, December 15th, 2017
  • Rohit Vanjani of "Guggenheim" Initiated at Hold and Held Target at $16 on, Tuesday, December 12th, 2017
  • Douglas Tsao of "Barclays" Maintained at Hold with Decreased Target to $19 on, Friday, October 20th, 2017


These are the ratings of the 5 analyists that currently disagree with Ami


  • Irina Rivkind Koffler of "Mizuho" Upgraded from Hold to Strong Buy on, Tuesday, January 9th, 2018
  • Jacob Hughes of "Wells Fargo" Downgraded from Hold to Sell on, Friday, January 5th, 2018
  • Liav Abraham of "Citigroup" Upgraded from Hold to Strong Buy on, Thursday, January 4th, 2018
  • Jami Rubin of "Goldman Sachs" Upgraded from Hold to Strong Buy on, Friday, December 15th, 2017
  • Chris Schott of "JP Morgan" Downgraded from Hold to Sell on, Monday, November 13th, 2017